Date: 2018-03-01
Type of information: Nomination
Compound: member of the board of directors
Company: Iovance Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 1, 2018, Iovance Biotherapeutics announced the appointment of Michael Weiser to Iovance’s Board of Directors, effective March 15, 2018. Dr. Weiser will serve as the chair of Iovance’s Compensation Committee and will serve on Iovance’s Nominating & Governance and Audit Committees. Dr. Weiser is the founder and currently the co-CEO of Actin Biomed, a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, a pharmaceutical development and healthcare investment firm. Dr. Weiser currently serves on the board of directors of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology, and on the board of directors of Emisphere Technologies, a pharmaceutical and drug delivery company. Dr. Weiser formerly served as the chairman of the board of directors of Chelsea Therapeutics International, a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine, and completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College.
Financial terms:
Latest news:
Is general: Yes
